The Instructions for Use (IFU) document is written for patients or their caregivers who use prescription drug and biological products that have complicated or detailed instructions. The recommendations in this guidance are intended to help provide consistency to the content and format of IFU documents and to help ensure that patients receive clear and concise information that is easily understood for the safe and effective use of such products.
This guidance finalizes the draft guidance that FDA issued in July 2019 titled “Instructions for Use — Patient Labeling for Human Prescription Drug and Biological Products and Drug-Device and Biologic-Device Combination Products — Content and Format, Guidance for Industry.” In the final guidance, FDA added clarifying language, consolidated discussions of human factors, and aligned the final guidance with the standards used in other Center for Drug Evaluation and Research policy documents.
This final guidance is a commitment included in the Prescription Drug User Fee Act (PDUFA) VI performance goals letter related to guidance on patient-oriented labeling (e.g., IFU documents).
FDA Issues Revised Draft Guidance on Charging for Investigational Drugs Under an Investigational New Drug Application
August 2022 Draft Guidance This guidance provides information for industry, researchers, physicians, institutional review boards (IRBs), and patients about the implementation of FDA’s regulations on...